switching between glp 1 agonists chart GLP‐1 receptor in clinical practice: Expert consensus and practical guidance Switching from tirzepatide to retatrutide:

Within participants with pre-existing SUDs, initiation of a GLP-1 receptor agonist was associated with reduced risk of SUD related emergency department visits (hazard ratio 0.69 (95% CI 0.61 to 0.78), NRD 8.92 (95% CI 11.59 to 6.25)), SUD related hospital admission (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and associated with reduced risk of the composite endpoint of the three outcomes (0.71 (0.65 to 0.79), NRD 11.79 (14.98 to 8.60)) (fig 6 and supplementary table S11)

This allows for the evaluation of the overall competition within the market

[DOI] [PubMed] [Google Scholar] 320.Lim G.E., Brubaker P.L

An important feature of GLP-1 RA use in type 2 diabetes is weight loss, which reduces insulin resistance and typically reaches a plateau after around 6 months of treatment

However, significant variations in control types (placebo, MET, or intensive lifestyle), concomitant medications, and follow-up windows mean that a robust head-to-head ranking of strategies is still lacking

Beyond obesity and type 2 diabetes, the therapeutic potential of GLP-1 RAs extends to a range of conditions such as cardiovascular disease, liver disease, neurodegenerative disease, and substance abuse disorders